Biocon Ltd (BIOCON) is currently trading at 390.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets. The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26. Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus. Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.

Over the past 52 weeks, Biocon Ltd has traded between a low of ₹337.20 and a high of ₹447.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Biocon Ltd has a market capitalization of approximately 63,712.89. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Biocon Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 153.01 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 63,712.89 Cr, Biocon Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Biocon Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Biocon Ltd is 153.01. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Biocon secured a 10-year supply contract for Pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis under the PDP programme.

Revenue from operations was ₹4,336 crore in Q1 FY27, up 10.00% year-on-year from ₹3,942 crore.

It announced a new settlement and licence agreement with Regeneron and Bayer covering Europe and the rest of the world, enabling worldwide commercialisation of Yesafili.

Yesafili is aflibercept-jbvf, a VEGF inhibitor and biosimilar to Eylea. It is associated with Biocon Biologics, a subsidiary of Biocon Ltd.